Xtant Medical Holdings, Inc.XTNTEarnings & Financial Report
Xtant Medical Holdings, Inc. is a global medical technology company that develops, manufactures and markets orthobiologic products, neurosurgery devices, and regenerative medicine solutions for orthopedic and neurological care providers. It serves patients and medical institutions across North America, Europe and the Asia-Pacific, with core segments covering spinal surgery supplies and bone regeneration products.
Revenue
$27.9M
Gross Profit
$17.3M
Operating Profit
$-3.5M
Net Profit
$-4.4M
Gross Margin
62.1%
Operating Margin
-12.4%
Net Margin
-15.8%
YoY Growth
55.3%
EPS
$-0.03
Xtant Medical Holdings, Inc. Q1 FY2024 Financial Summary
Xtant Medical Holdings, Inc. reported revenue of $27.9M (up 55.3% YoY) for Q1 FY2024, with a net profit of $-4.4M (down 111.7% YoY) (-15.8% margin). Cost of goods sold was $10.6M, operating expenses totaled $20.8M.
Key Financial Metrics
| Total Revenue | $27.9M |
|---|---|
| Net Profit | $-4.4M |
| Gross Margin | 62.1% |
| Operating Margin | -12.4% |
| Report Period | Q1 FY2024 |
Revenue Breakdown
Xtant Medical Holdings, Inc. Q1 FY2024 revenue of $27.9M breaks down across 2 segments, led by US at $25.1M (90.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| US | $25.1M | 90.2% |
| Rest Of World | $2.7M | 9.8% |
Xtant Medical Holdings, Inc. Annual Revenue by Year
Xtant Medical Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $133.9M).
| Year | Annual Revenue |
|---|---|
| 2025 | $133.9M |
| 2024 | $117.3M |
| 2023 | $91.3M |
| 2022 | $58.0M |
Xtant Medical Holdings, Inc. Quarterly Revenue & Net Profit History
Xtant Medical Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $32.4M | +2.7% | $57.0K | 0.2% |
| Q3 FY2025 | $33.3M | +19.0% | $1.3M | 3.9% |
| Q2 FY2025 | $35.4M | +18.3% | $3.5M | 10.0% |
| Q1 FY2025 | $32.9M | +18.0% | $58.0K | 0.2% |
| Q4 FY2024 | $31.5M | +12.1% | $-3.2M | -10.0% |
| Q3 FY2024 | $27.9M | +11.7% | $-5.0M | -18.0% |
| Q2 FY2024 | $29.9M | +48.0% | $-3.9M | -12.9% |
| Q1 FY2024 | $27.9M | +55.3% | $-4.4M | -15.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.9M | $29.9M | $27.9M | $31.5M | $32.9M | $35.4M | $33.3M | $32.4M |
| YoY Growth | 55.3% | 48.0% | 11.7% | 12.1% | 18.0% | 18.3% | 19.0% | 2.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $93.9M | $95.6M | $98.9M | $93.8M | $95.8M | $103.5M | $106.3M | $94.1M |
| Liabilities | $46.3M | $50.6M | $53.2M | $50.9M | $52.0M | $55.0M | $55.9M | $43.2M |
| Equity | $47.7M | $45.0M | $45.7M | $43.0M | $43.9M | $48.5M | $50.4M | $51.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.8M | $-5.1M | $-1.7M | $665000 | $1.3M | $1.3M | $4.6M | $5.4M |